Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
CHARLOTTE, NC, June 29, 2007-This week, Appian International Research, Inc. announced plans to expand its generic pharmaceuticals development services as the company enters its second year.
“Appian International Research as a company is still relatively new to the industry, but our team certainly isn’t,” explained Appian’s President, Dr. Grier Harris.
“Appian International Research is the outgrowth of Appian Services, a consulting firm that we established in 2003 to provide contract development services to generic and small Pharma companies. We help our clients manage strategic development plans, designed study protocols, compiled reports, and performed site audits, whatever it took to help them overcome the hurdles inherent in pharmaceutical product development. As business grew, we decided to focus on our expanding network of international resources and broaden our range of services.”
“Our specialty, of course, is the design and management of clinical endpoint bioequivalence trials, the sort of trials that the FDA’s Office of Generic Drugs requires for the approval of topically active drugs. Most of our early work has been in dermatological products, but we are currently expanding into some other therapeutic areas that will take advantage of the many years of experience that we have in topical drug development.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
